RecruitingNot ApplicableNCT06929533

Pharmacogenomics-Supported Psychotropic Prescribing Trial

Pharmacogenomics-Supported Psychotropic Prescribing Trial (PGx-SUPPORT): A Pilot Implementation Study in Manitoba

Sponsor

University of Manitoba

Enrollment

200 participants

Start Date

Jul 1, 2025

Study Type

INTERVENTIONAL

Conditions

Adverse Drug Reaction (ADR)Effectiveness Mental Disorder Pharmacogenetics

Summary

Investigate the feasibility and utility of implementing pharmacogenetic testing for adults (aged 18 and older) seeking care for mental illness in Manitoba.

Eligibility

Min Age: 18 Years

Inclusion Criteria3

Aged 18 years or older
The initiation, change, dose adjustment, or augmentation of psychotropic medication(s) is indicated
The treating clinician thinks PGx testing can benefit and refers the patient to the study

Exclusion Criteria4

Unwillingness to donate saliva samples for genetic analysis
History of liver or bone marrow (hematopoietic cell) transplantation
PGx testing results are already available
No personal health identification number (PHIN) is available

Interventions

DIAGNOSTIC_TESTPharmacogenetic Testing

Participants will donate a 1ml (one-fifth of a teaspoon) sample of saliva. DNA extracted from the saliva sample will be used for genotyping. Genotyping results will be translated into an interpretative clinical report using evidence-based software (Sequence2Script) and delivered to the treating physician for use in their clinical decision-making. The report will contain genotyping results, predicted phenotype, and evidence-based drug selection and dosing recommendations relevant to the patient's current and future care.